Amgen – Buy Signal
Amgen Inc. – Common is under Algo Engine buy conditions and is a current holding in our US S&P100 model portfolio.

Amgen Inc. – Common is under Algo Engine buy conditions and is a current holding in our US S&P100 model portfolio.

Cochlear is now under Algo Engine buy conditions and has been added to our ASX 100 model portfolio.
We expect 10% EPS growth over the next 12 months. Although, the stock remains expensive at 40x earnings and trading on a 1.8% yield.

Since writing the above post in Dec last year, COH has rallied from $175 to a high of $257. The subsequent pullback which bottomed on Monday this week has seen buying interest rebuild at the higher low of $222.
This is the second cluster of Algo Engine buy signals and we’ve taken the opportunity to add to our original allocation.

Australian Pharmaceutical Industries is under Algo Engine buy conditions.

We’ll increase our research coverage for API in the coming days.
Altium is under Algo Engine buy conditions.

Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
Reece is now under Algo Engine buy conditions.
The FY21 result highlighted strong sales trends in both Australia and
the US, however, costs in the US dampened the operating profit.
The market is looking for 10% EPS growth into FY22 and FY23 which places REH on 30X forward earnings and 1% dividend yield.

Cleanaway Waste Management is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.

Cleanaway financial results for the year ended 30 June 2021
Statutory Net Profit After Tax (NPAT) increased 31.2% from $112.6 million to $147.7 million.
On an Underlying basis compared to the year ended 30 June 2020 (“FY20”) Cleanaway reported:
• NPAT increased 2.1% from $150.0 million to $153.2 million
• EBITDA increased 3.8% from $515.7 million to $535.1 million
• Net revenue increased 4.7% from $2.1 billion to $2.2 billion
• Operating cash flow increased 5.7% from $401.5 million to $424.4 million
• Final dividend increased 11.9% from 2.10 cents per share (cps) to 2.35 cps, taking the total dividend for the year 12.2% higher to 4.60 cps

Zip Co is under Algo Engine buy conditions.
Revenue was up 150% to $403m and the pre-tax loss -$718m.
Zip said its cash earnings before tax, depreciation and amortisation loss was $22.9 million, which missed consensus expectations for positive earnings of between $8 million and $9 million.
Its total reported loss of $653 million was just below the total amount of capital that Zip raised over the year to support its global growth.
We’re watching ZIP with a great deal of interest but remain cautious on the sector trends with regards to increasing bad debts.

Clinuvel Pharmaceuticals is under Algo Engine buy conditions. Company revenues increased 47% in FY21, helping to boost profits by nearly two-thirds to $24.7 million. The revenues were powered by strong patient demand in Europe and the US.
